Scott S. Tykodi, MD, PhD

home / authors / scott-s.-tykodi,-md,-phd

Articles

Dr. Tykodi on the KEYNOTE-427 Trial With Pembrolizumab in RCC

Dr. Tykodi on the KEYNOTE-427 Trial With Pembrolizumab in RCC

Scott S. Tykodi, MD, PhD
August 11th 2020

Scott S. Tykodi, MD, PhD, provides background to the phase 2 KEYNOTE-427 trial with pembrolizumab in renal cell carcinoma.

Read More

Dr. Tykodi on the Clinical Implications of the KEYNOTE-427 Trial in Advanced RCC

Dr. Tykodi on the Clinical Implications of the KEYNOTE-427 Trial in Advanced RCC

Scott S. Tykodi, MD, PhD
August 10th 2020

Scott S. Tykodi, MD, PhD, discusses the clinical implications of the phase 2 KEYNOTE-427 trial in advanced renal cell carcinoma.

Read More

Dr. Tykodi on the Efficacy of Dual Checkpoint Blockade in RCC

Dr. Tykodi on the Efficacy of Dual Checkpoint Blockade in RCC

Scott S. Tykodi, MD, PhD
June 25th 2020

Scott S. Tykodi, MD, PhD, discusses the efficacy of dual checkpoint blockade in renal cell carcinoma.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data